Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sousa-Pinto Bernardo, Costa Elísio M, Vieira Rafael José, Klimek Ludger, Czarlewski Wienczyslawa, Pfaar Oliver, Bedbrook Anna, Amaral Rita, Brussino Luisa, Kvedariene Violeta, Larenas-Linnemann Desiree E, Iinuma Tomohisa, Pham-Thi Nhân, Regateiro Frederico S, Taborda-Barata Luis, Ventura Maria Teresa, Ansotegui Ignacio J, Bergmann Karl C, Canonica G Walter, Cardona Victoria, Cecchi Lorenzo, Cherrez-Ojeda Ivan, Cingi Cemal, Cruz Alvaro A, Del Giacco Stefano, Devillier Philippe, Fokkens Wytske J, Gemicioglu Bilun, Haahtela Tari, Ivancevich Juan Carlos, Kuna Piotr, Kraxner Helga, Laune Daniel, Louis Renaud, Makris Michael, Morais-Almeida Mario, Mösges Ralph, Niedoszytko Marek, Papadopoulos Nikolaos G, Patella Vincenzo, Pereira Ana Margarida, Reitsma Sietze, Robles-Velasco Karla, Rouadi Philip W, Samolinski Boleslaw, Sova Milan, Toppila-Salmi Sanna K, Sastre Joaquin, Valiulis Arunas, Yorgancioglu Arzu, Zidarn Mihaela, Zuberbier Torsten, Fonseca Joao A, Bousquet Jean, MASK‐air think tank
Аннотация
METHODS: We included regular European MASK-air users with self-reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine-fluticasone. We assessed weeks during which patients answered the MASK-air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom-medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data.
RESULTS: We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine-fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self-reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co-medication. The sensitivity analyses displayed similar results.
CONCLUSIONS: A high adherence was found in patients reporting regular use of MASK-air. Different adherence patterns were found for INCS compared to OAH or azelastine-fluticasone that are likely to impact guidelines.